Search
for
Sort by
Research 301–330 of 781
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
- Transcriptional Profiling in Rat Hair Follicles following Simulated Blast Insult: A New Diagnostic Tool for Traumatic Brain Injury
- Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management
- Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity
- Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
- Increase in IL-15 levels in patients with alopecia areata
- Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
- Fibroblast heterogeneity and functions: insights from single-cell sequencing in wound healing, breast cancer, ovarian cancer and melanoma
- Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome
- British Society for Dermatopathology
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Patient Validation of Estimation of Health Utility Values in Alopecia Areata
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
- Oxidative stress and alopecia areata
- Clinical response to oral tofacitinib in pediatric patients with alopecia areata
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Hair follicle targeting via gelatin coated transferosomes loaded with tofacitinib citrate for enhanced treatment of alopecia areata: Clinical evaluation of alopecia areata patients
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
- Interleukin-15 is a hair follicle immune privilege guardian
- Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata
- Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme